Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Goflikicept by R-Pharm for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome: Likelihood of Approval
Goflikicept is under clinical development by R-Pharm and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory...
Bevacizumab biosimilar by R-Pharm for Ovarian Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by R-Pharm and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...
Bevacizumab biosimilar by R-Pharm for Metastatic Colorectal Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by R-Pharm and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData,...
Bevacizumab biosimilar by R-Pharm for Glioblastoma Multiforme (GBM): Likelihood of Approval
Bevacizumab biosimilar is under clinical development by R-Pharm and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData,...
Bevacizumab biosimilar by R-Pharm for Non-Small Cell Lung Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by R-Pharm and currently in Phase I for Non-Small Cell Lung Cancer. According to...
Bevacizumab biosimilar by R-Pharm for Breast Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by R-Pharm and currently in Phase I for Breast Cancer. According to GlobalData, Phase...
Olokizumab by R-Pharm for Idiopathic Interstitial Pneumonia (IIP): Likelihood of Approval
Olokizumab is under clinical development by R-Pharm and currently in Phase III for Idiopathic Interstitial Pneumonia (IIP). According to GlobalData,...
Olokizumab by R-Pharm for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease): Likelihood of Approval
Olokizumab is under clinical development by R-Pharm and currently in Phase III for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease)....
Olokizumab by R-Pharm for Sarcoidosis: Likelihood of Approval
Olokizumab is under clinical development by R-Pharm and currently in Phase III for Sarcoidosis. According to GlobalData, Phase III drugs...